

PROCESS SCALE-UP CRITERIA IN PRODUCTION OF RECOMBINANT PROTEINS IN *E. COLI*: A SYSTEMATIC REVIEW

ABEIR HUSSEIN MOHAMED GAMEIL¹, FARIDAH YUSOF^{1*}, AZLIN SUHAIDA AZMI¹, NOOR ILLI MOHAMAD PUAD¹

¹Dept. of Biotechnology Engineering, Kulliyah of Engineering, International Islamic University Malaysia, Kuala Lumpur, Malaysia

*Corresponding author: yfaridah@iium.edu.my

ABSTRACT: This systematic review provides an overview of the scale-up of recombinant protein production. A systematic search was conducted using pre-established terms in four electronic databases (PubMed, Europe PMC, Science Direct, and Scopus), and included journal articles published between 1999 to 14 November 2019. Studies that met the inclusion and exclusion criteria specified were included. Initially, 665 abstracts were screened, of which 595 were excluded. A further 58 articles were excluded after full-text review and 14 articles underwent quality assessment. Finally, only eight (8) eligible articles were identified and included in this review. Oxygen transfer, shear, and production costs were identified as the main factor that affected the choice and success of a scale-up strategy. The comparison of different fermentation systems revealed that maintaining the k_{La} constant was found to be effective in all included studies which employed it, and superior in the two studies that compared it to other criteria. Risk of bias assessment revealed that publication bias and reporting bias are significant issues to be considered in scale-up. Overall, these findings provide insight that can assist researchers to improve the scaling up of fermentation processes and achieve a successful scale-up of recombinant protein production using *E. coli* as the host.

KEYWORDS: Scale-up, *Escherichia coli*, Fermentation, Recombinant Protein, and Bioreactor

1. INTRODUCTION

1.1. Background of study

Genetic engineering has been employed to produce a variety of proteins in amounts required for research, clinical, as well as industrial purposes via microbial cultures [1-2]. *Escherichia coli* (*E. coli*) is the leading toiler and model organism for recombinant protein production, and it has been used to produce numerous recombinant proteins such as enzymes, growth factors, and viral proteins. *E. coli* offers a superior expression system for many fermentations, because of its rapid growth and uncomplicated cultivation [2-3]. Furthermore, there has been a great deal of research effort into the engineering of various strains of *E. coli*, vector development, fermentation media, various modes of bioreactor operation, kinetics modeling, and metabolomics, as well as induction- and expression-related parameters. As such, it is the leading candidate to produce a new recombinant protein [2-3].

A fermentation process is developed in three stages; namely bench or laboratory scale, pilot scale, and full-scale manufacturing. First, fermentation conditions are optimized at the smallest scale to preserve resources and reduce costs associated with the fermentation experiments. Once successful production is established at the laboratory scale, the bioprocess may be upscaled to maintain or improve yield on a larger scale and eventually at an industrial scale to provide large quantities of the protein through a cost-effective, commercially viable manufacturing process. It is only when the desired product yields at both the small-scale and large-scale are similar or are comparable that the scale-up is considered a success. This scale-up, however, is not a straightforward task that can be linearly extrapolated from data at a small-scale. Each fermentation process is a unique and complex system, governed by genetic and environmental factors, that involves a cell that is a complex system that will require an understanding of its metabolic mechanism of response. Factors such as expression strain, fermentation medium, and operating conditions, all play important roles in the process [4]. It is important, therefore, to identify an appropriate parameter or set of parameters that will be critical to the specific fermentation case. Thus, scale-up can be approached in a variety of ways and generally requires a scale-up strategy. Some papers reported successful scale-up from the microplate culture or shake flask culture, however, these studies require separate analysis and cannot be considered together with this study which includes stirred tank bioreactor cultures. This is because the vessel geometry and aeration and agitation methods will not be similar at both scales, thus rendering any comparison difficult [4].

There are many strategies from which researchers can successfully perform a process scale-up, including maintaining a constant power input per unit volume, the volumetric gas flow rate per unit volume of liquid, superficial gas velocity, impeller tip speed, mixing time, and impeller Reynolds number [4]. Although all these criteria are important for a process, it is impossible to control all of them or to maintain them constant simultaneously without the involvement of automated control systems and artificial intelligence. Hence, it is critical to identify which criteria will be more imperative for a process. For an instance, for a fast-chemical reaction, constant mixing time might be more valuable as a scale-up parameter. In the case of aerobic fermentation, more than often one of these scale-up strategies is to maintain constant oxygen transfer or k_La . This is because oxygen has limited solubility in water (and fermentation media) and will often be the limiting substrate in the aerobic reaction where a continuous supply is needed. Hence, the oxygen transfer must be determined or predicted for aerobic fermentation. There are many ways that this can be achieved, using models that correlate k_La to another parameter. However, other factors will constrain what will be a realistic process, for example, constraints on power consumption or maximum shear acceptable to the cells. Then, models that consider these constraints on power consumption and impeller tip speed can be used to obtain realistic upscaled processes [1, 4]. Therefore, this paper aims to explore recent studies, highlighting the strategies and criteria employed in the scale-up of recombinant protein production in *E.coli* and their implications. In addition, this paper also includes some studies that attempted to provide solutions to resolve problems faced during scale-up.

1.2. Research Questions

The research questions this paper seeks to answer are as follows:

1. What process scale-up methods or strategies have been applied to or used with *E. coli* to produce recombinant proteins?

2. What is the effect of various process and operation conditions on protein production in scale-up?
3. What are the problems experienced in the included papers and how were they resolved?

2. MATERIALS AND METHODS

2.1. PRISMA Guidelines

This systematic review was carried out by following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [5]. The keywords were determined using the PICOC system, as shown in Table 1.

Table 1: PICOC (Population, Interventions, Comparisons, Outcomes, and Context of study) summary used to develop the search terms

Study characteristic	Keywords
Population	recombinant <i>E. coli</i>
Intervention	process scale-up
Comparison	scale-up strategies
Outcome	recombinant protein and biomass yield
Context	fermentation

2.2. Eligibility Criteria

English-language studies published between 1999 to 14 November 2019 were the only articles considered in this study. As only journal articles are included in this study, thus, review articles, conference papers and proceedings, and book sections were excluded. This is to exclude the results of “grey” literature, which may not have been obtained through systematic methods.

2.3. Information Sources

The systematic searches were performed in the databases as shown in Table 2. Additional papers were obtained through forward and backward ‘snowballing’ (citation searching) techniques [5]. This refers to manually browsing the reference lists of accepted articles after the screening had been completed, as well as using suggestions from the databases and search engines that show relevant papers citing the accepted articles.

Table 2: Databases used in this review

Database	Organization/Institution	URL
Europe PMC	National Center for Biotechnology Information	https://europepmc.org/
PubMed	National Center for Biotechnology Information	https://www.ncbi.nlm.nih.gov/pubmed/advanced
ScienceDirect	Elsevier	https://www.sciencedirect.com/
Scopus	Elsevier	http://www.scopus.com
Additional sources	-	-

2.4. Search Strategy

The keywords and synonyms presented in Table 3 were considered for formulating the search strings. The search strings in Table 4 were used with their corresponding databases or digital libraries.

Table 3: Keywords and their synonyms used to formulate the database search strings

Keyword	Synonyms
Constant k_{La}	Constant oxygen mass transfer
<i>E. coli</i>	<i>Escherichia coli</i>
Process	Expression, fermentation, production, bioprocess
Recombinant Proteins	Heterologous protein
Scale-up	Large-scale, pilot-scale, scalable, scaleup, scale-up, upscaled
Scale-up strategies	constant k_{La} , constant oxygen mass transfer, constant power, tip speed
Yield	-

Table 4: Databases, keywords, and dates of the latest searches

Database	Search	Date last searched
Europe PMC:	KW: "recombinant" AND ("bioreactors" OR "fermentation") AND "coli" AND ("scale-up" OR "scaleup" OR "scale up" OR "upscaled")	14 November 2019
PubMed:	((("scaleup"[Title] OR "scale up"[Title] OR "scale-up"[Title] OR "scalable"[Title] OR "upscale*" [Title] OR "*-scale"[Title] OR "pilot"[Title] OR "industrial"[Title] OR "bench"[Title])) AND (bioreactors [MeSH Term] OR industrial microbiology[MeSH Term] OR fermentation [Title] OR bioprocess[Title] OR production[Title] OR process* [Title] OR kla[Title] OR bioreactor[Title] OR oxygen[Title])) AND (Escherichia coli[MeSH Term] OR coli[Title])) AND (yield [Title/Abstract] OR recombinant [Title/Abstract])	14 November 2019
ScienceDirect:	Title-Abstract-Keyword field: "recombinant" AND "coli" AND ("bioreactors" OR "fermentation" OR "bioprocess" OR "production" OR "process" OR "kla" OR "oxygen") Title field: ("scale-up" OR "scaleup" OR "scale up" OR "upscale" OR "scalable" OR "-scale" OR "pilot" OR "industrial")	14 November 2019
Scopus:	(TITLE ("scaleup" OR "scale up" OR "scale-up" OR "scalable" OR "upscale*" OR "*-scale" OR "pilot" OR "industrial" OR "bench") AND TITLE-ABS-KEY (bioreactors OR industrial AND microbiology OR fermentation OR bioprocess OR production OR process* OR kla OR bioreactor OR oxygen) AND TITLE-ABS-KEY (escherichia AND coli OR coli) AND TITLE-ABS-KEY (yield OR recombinant))	14 November 2019

2.5. Study Selection and Data Extraction

Parsifal, an online tool for systematic literature reviews, was used to manage the methodology planning, conduct screening, and qualitative analysis (<https://parsif.al/Xochitl89/process-scaleup-criteria-in-production-of-recombinant-proteins-in-e-coli-a-systematic-review/settings/>). Zotero software (Version 5.0.88) was used to manage the bibliography. Duplicates were removed. All titles and abstracts retrieved from the comprehensive search were independently screened and evaluated based on the inclusion and exclusion criteria as shown in Table 5.

Table 5: Inclusion and exclusion criteria

Type	Criteria
Inclusion	<ol style="list-style-type: none"> 1. Must have protein expression 2. Recombinant <i>E. coli</i> fermentation 3. Studies must report the specific recombinant protein quantities 4. Studies must involve a fermentation process scale-up or comparison of at least 2 scales
Exclusion	<ol style="list-style-type: none"> 1. Reviews, communications, conference papers, theses, and dissertations 2. Not stirred tank reactors 3. Not in the English language 4. Older than 20 years

The bibliographies of included studies were checked for additional publications. Full texts of selected articles were then obtained. The full texts of accepted articles then underwent full-text eligibility assessment to ensure they comply with the inclusion and exclusion criteria, as some titles, abstracts, and even keywords were unclear or ambiguous. Accepted articles that passed the full-text screening were then subjected to quality assessment.

Stirred tank bioreactors are the most used bioreactor type for a large variety of bioprocesses, both at the laboratory and industrial scale, as they provide high mass and heat transfer rates and excellent mixing. Furthermore, it is more convenient to carry out the scale-up procedure in stirred tank bioreactors as they come in numerous sizes, up to 20, 000 L, with similar geometries. Consequently, this review focused on scale-up studies in stirred tank reactors only [4].

2.6. Quality Assessment Checklist

To ensure that the accepted papers are of sufficient standard to be analyzed, the questions in Table 6 were used as guidelines. The possible answers and their respective weights are also shown. The maximum score is 3.0. The cutoff score is 2.5 Therefore, any paper that had a score that was lower or equal to 2.5 was deemed unfit to be included in the discussion of this study.

Table 6: Quality assessment questions and their weighted answers

Questions	Possible answers		
	Yes	Partially	No
Is the scale-up strategy clearly specified?	1.0	0.5	0.0
Are the fermentation parameters reported for each scale?	1.0	0.5	0.0
Are the data collection methods adequately detailed?	1.0	0.5	0.0

2.7. Risk of Bias Assessment

Bias, in academic research, may be defined as the introduction of a systematic error into the research methodology, whether in the study design, data collection or analysis, or publication stages, by selecting or encouraging one outcome or answer over others, thus preventing an objective consideration of a research question [6]. The interpretation of bias requires more than a simple yes or no answer, and instead it is important to describe the degree of bias. To assess the risk of bias, accepted papers underwent the risk of bias assessment for individual studies. In addition to the above quality assessment questions, the questions in Table 7 were posed.

Table 7: Risk of bias assessment questions

Risk of bias assessment question	Related bias
Are reports of the study free of selective outcome reporting?	Reporting bias, publication bias
Was the statistical analysis for all results reported?	Reporting bias, publication bias
Is incomplete outcome data addressed?	Attrition bias

The level of bias was assessed as a judgment (high, low, or unclear) for individual elements from five areas (selection, performance, attrition, reporting, and other biases). Selection bias is a type of bias that occurs mostly in clinical studies where there is no blinding in choosing the population of study due to convenience or other factors thereby introducing bias. Performance bias occurs due to the knowledge of the researchers or participants involved in the intervention, thus skewing the findings. Attrition bias occurs when some participants in the study do not complete the study. Again, this is often observed in clinical trials. Reporting bias occurs when there is selective reporting of only positive results that would fit the hypothesis. Publication bias is a type of bias that occurs when the results of an experiment or research study influence the decision of whether to publish or otherwise distribute it. This failure in reporting results then affects the ability of accurate synthesis and description of evidence in that area of research. It then leads to wrong conclusions as well as a waste of research opportunities, efforts, and money [7].

2.8. Data Extraction and Data Collection Process

The results of each stage of this systematic review were recorded and are presented in the subsequent section. All titles, abstracts, and full-text articles, and performed the quality assessment were screened. The authors concurred, through consensus, on relevance, protocol, findings, quality and risk assessment, and conclusions. Funding information was also obtained for papers included in the systematic review. Table 8 presents the information extracted from the included papers. Recombinant protein yield, biomass yield, and recombinant protein activity (where available instead of protein yield or productivity) at both small and large scales were the main evaluated outcomes. These parameters were used to generate a form using the Parsifal tool to collect and store the data for each included paper.

Table 8: Data extracted from the small-scale and large-scale fermentations in each study

Type of Variable	Parameter
Controlled	<i>E. coli</i> strain
	Fermentation mode
	Fermentation medium
	Vessel volume
	Working volume
Measured	Scale-up strategy (including dimensions, and agitation, and oxygen-related parameters)
	Biomass production
	Protein production

3. RESULTS

3.1. Study Selection and PRISMA Flow Diagram

The systematic search returned a total of 872 citations results, including duplicates. These papers were then imported into the online Parsifal tool, using TexMed and Zotero

tools where a direct import was not possible. Imported studies were made up of 285 records identified through Europe PMC, 2133 records from PubMed, 274 through Scopus, 99 from Science Direct, and one additional paper from references. Of these, 665 abstracts were screened, after the removal of duplicate articles, and 595 were excluded by title and/or abstract screening. The 72 records went through full-text screening and finally, 14 papers underwent quality assessment. A total of eight (8) eligible articles were identified and included in the final review [8-15]. Table 9 shows all the 58 excluded full-text articles and reasons for exclusion and six (6) included articles but whose quality was rejected [16-77]. Fig. 1 summarizes this process and results.

Table 9: Excluded full-text articles and reasons for exclusion (n=58) and those included but whose quality was rejected (n=8)

No.	Reference	Reason for rejection
1	[16]	Not comparing 2 STR scales
2	[17]	Not comparing 2 STR scales
3	[18]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
4	[19]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
5	[20]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
6	[21]	Not comparing 2 STR scales
7	[22]	Not comparing 2 STR scales
8	[23]	Not comparing 2 STR scales
9	[24]	Not comparing 2 STR scales
10	[25]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
11	[26]	Not comparing 2 STR scales
12	[27]	Not comparing 2 STR scales
13	[28]	Not comparing 2 STR scales
14	[29]	Not comparing 2 STR scales
15	[30]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
16	[31]	Quality rejected
17	[32]	Not comparing 2 STR scales
18	[33]	Not comparing 2 STR scales
19	[34]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
20	[35]	Quality rejected
21	[36]	Not comparing 2 STR scales
22	[37]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
23	[1]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
24	[38]	Not comparing 2 STR scales
25	[39]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
26	[40]	Not comparing 2 STR scales
27	[41]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
28	[42]	Not comparing 2 STR scales
29	[43]	Not comparing 2 STR scales
30	[44]	Not comparing 2 STR scales
32	[3]	Not comparing 2 STR scales
31	[45]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
33	[46]	Not comparing 2 STR scales
34	[47]	Not comparing 2 STR scales
35	[48]	Quality rejected
36	[49]	Not STR
37	[50]	Not comparing 2 STR scales
38	[51]	Not comparing 2 STR scales
39	[52]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
40	[53]	Quality rejected
41	[54]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
42	[55]	Quality rejected
43	[56]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
44	[57]	Not comparing 2 STR scales
45	[58]	Not comparing 2 STR scales
46	[59]	Not comparing 2 STR scales
47	[60]	Not comparing 2 STR scales
48	[61]	Not comparing 2 STR scales

49	[62]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
50	[63]	Quality rejected
51	[64]	Not comparing 2 STR scales
52	[65]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
53	[66]	Not comparing 2 STR scales
54	[67]	Not comparing 2 STR scales
55	[68]	Not comparing 2 STR scales
56	[69]	Not comparing 2 STR scales
57	[70]	Not comparing 2 STR scales
58	[71]	Not comparing 2 STR scales
59	[72]	Does not involve a fermentation scale-up study or comparison of at least 2 scales
60	[73]	Not comparing 2 STR scales
61	[74]	Not comparing 2 STR scales
62	[75]	Not comparing 2 STR scales
63	[76]	Not comparing 2 STR scales
64	[77]	Not comparing 2 STR scales




Fig. 1. Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) flow diagram of this study.

3.2. Study Characteristics

The findings of each study were analyzed and extracted data were summarized into several tables. Table 10 provides information related to recombinant protein production, scale-up strategies employed, and observations. Table 11 summarizes the fermentation details reported including fermentation mode, media used, carbon and nitrogen sources used, and inoculum sizes. It can be surmised that only batch or fed-batch modes of operation are typically analyzed in scale-up studies. The strains of *E. coli* employed varied, though the BL strain is quite commonly used. The type of media used for the culture also varied across studies. However, glucose was used as the carbon source in all papers indicating it is suitable for growing recombinant *E. coli* of various strains. There is not enough reported data in these papers to analyze inoculum size across studies.

Table 10: Scale-up for recombinant proteins production in *E. coli*

Study	Protein	Scale-up strategies	Vessel volume and working volume (in liters)		Measured variables	Observations
			SS	LS		
[8]	Antigen K99	constant k_{La} constant Q/V	5 (NA)	200 (NA)	<ul style="list-style-type: none"> • K99 productivity (mg/L.h) • cell specific growth rate (/h) 	<ul style="list-style-type: none"> • A slightly reduced yield of biomass and K99 product was noted upon scale-up. • Similar growth rates at both scales.
9]	Antigen K88	constant k_{La} constant Q/V	5 (NA)	50 (NA)	<ul style="list-style-type: none"> • K88 production (mg/L), OD530 	<ul style="list-style-type: none"> • Similar at both scales, thus validating the choice of scale-up strategy.
[10]	IL-1 receptor antagonist	constant DO	2 (1.6)	100 (NA)	<ul style="list-style-type: none"> • OD600, Productivity 	<ul style="list-style-type: none"> • Reduced cell growth and productivity were observed, due to differences in oxygenation and stress.
[11]	Outer membrane protein Opc	constant P/V constant k_{La}	NA (1.5)	NA (50)	<ul style="list-style-type: none"> • Cell dry weight (g/L) • Opc production (mg/L) 	<ul style="list-style-type: none"> • Using constant P/V, the protein productivity dropped to 26 mg/L/h from 49 mg/L/h. Thus, the aeration rate was recalculated using k_{La}.
[12]	P46k protein	constant nDi constant k_{La} /k constant P/V constant Re	2.5 (1.5)	70 (50)	<ul style="list-style-type: none"> • Cell dry weight (g/L) • P64k • Protein Production (mg/L) 	<ul style="list-style-type: none"> • Cell dry weight and protein production dropped when a constant Reynolds number was used, and the degree of agitation dropped. In contrast, they improved with other criteria, when compared to small scale and were highest for constant k_{La}. All

						criteria except constant Re resulted in similar agitation speed values, though constant k_{La} did so without an increase in shear as experienced with constant P/V .
[13]	Phosphotriesterase-like lactonase	constant DO	2.5	150	<ul style="list-style-type: none"> • Enzyme production (mg/L) • Final biomass (g CWW¹/L) 	<ul style="list-style-type: none"> • Similar, slightly higher yields of the enzyme (37.6 to 39.7) and biomass (108 to 130) were obtained. • Acetate formation, cell density decreased, and product inhibition. Thus, galactose was used as an inducer instead of IPTG.
[14]	Granulocyte colony-stimulating factor (GCSF)	geometric similarity constant DO	2 (1)	13(8)	<ul style="list-style-type: none"> • Final cell density (DCW²/L)) • GCSF concentration (g/L) 	<ul style="list-style-type: none"> • Final cell density and amount of recombinant protein decreased significantly, due to acetate accumulation and heterogeneous conditions. • Plasmid stability decreased from 95% to 90% upon scaleup. This was attributed to a decrease in growth rate due to

								heterogeneous conditions inside the bioreactor, suggesting that there was a low oxygen concentration in some areas.
[15]	Human-like collagen (HLC)	constant p^*k_{La}	12.8 (6)	30 (15.4)	• growth (g DCW/L) and HLC concentration (g/L)	• The importance of the initial culture volume was highlighted.	• Acetate overproduction was observed.	

CWW= cell wet weight

²DCW= dry cell weight

*SS refers to Small Scale fermentation and LS refers to Large Scale fermentation

Table 11: Fermentation medium and carbon source used for each paper

Reference	Medium	Carbon source	Strain	Inoculum size	Operation Mode	Biomass production (SS)	Biomass production (LS)	Protein production (SS)	Protein production (LS)
[8]	Defined	glucose	MC1061	1% (v/v)	Batch	NA	NA	29.7 mg/L	30.1 mg/L
[9]	Defined	glucose	BB4	2% (v/v)	Batch	NA	NA	151.4 mg/L	NA
[10]	Terrific Broth	glucose	BLR (DE3)	NA	Fed-Batch	150	105	8.0 g/L	6.7 g/L
[11]	Modified Media	glucose	K12 GC366	NA	Batch	3 g/L	4 g/L	418 mg/L	520 mg/L
[12]	Modified Media	glucose	K12 GC366	NA	Batch	2.6 g/L	3.9 g/L	284 mg/L	546 mg/L
[13]	Semi-defined	glucose	BL21 (DE3)	NA	Fed-batch	108.1 g CWW/L	130.2 g CWW/L	37.6 U/g CWW	39.7 U/g CWW
[14]	Modified M9	glucose	BL21 DE3	NA	Batch	124.0 g DCW/L	114.0 g DCW/L	22.0 g/L	19.0 g/L
[15]	Luria Broth	glucose	BL21 pNWCP31	10% (v/v)	Fed-Batch	80.3 g/L	59.7 g/L	13.1 g/L	6.25 g/L

*SS refers to Small Scale fermentation, and LS refers to Large Scale fermentation.

Table 12 reports the findings of the included studies, in terms of biomass yield and recombinant protein yield at both the small and large scales. It also includes the strategies employed and whether they were reported as successful or not. Most of the strategies were reported as successful except for two strategies [11-12]. The former study [11] reported 257 mg/L Opc protein yield using constant P/V as a scaleup strategy, whereas the starting yield in the small-scale was 418 mg/L as the aeration rate was too low. The latter, [12], keeping the Reynolds number constant in scaleup resulted in a P64k protein yield of only 168 mg/L whereas the small-scale production had yielded 284 mg/L P64k protein. This is due to severely reduced agitation speed, and k_{La} . By comparison, all other strategies,

yielded values equal to 383 mg/L or higher. All studies were able to achieve successful scale-up using at least one criterion, even though in some cases some strategies attained lower protein yields on the large scale [10, 14-15] compared to the small scale. In the subsequent section, the specific results for each of the studies reviewed are elaborated.

Table 12: Scale-up parameters applied and resulting biomass and protein production (assessed by protein yield or activity)

Reference	Constant Parameter	Biomass production in Small Scale	Biomass production in Large Scale	Protein production in Small Scale	Protein production in Large Scale	Reported as successful
[8]	k_{LA} and Q/V	NA	NA	29.7 mg/L	30.1 mg/L	Yes
[9]	k_{LA} and Q/V	NA	NA	151.4	NA	Yes
[10]	DO	OD ₆₀₀ = 150 29 g DCW/L	OD ₆₀₀ = 105 NA	8.0 g/L	6.7 g/L	Yes
[11]	k_{LA} P/V	3 g/L 3 g/L	4 g/L 2 g/L	418 mg/L 418 mg/L	520 mg/L 257 mg/L	Yes No
[12]	k_{LA}/k Re NDi P/V	2.6 g/L 2.6 g/L 2.6 g/L 2.6 g/L	3.9 g/L 1.4 g/L 2.7 g/L 3.0 g/L	284 mg/L 284 mg/L 284 mg/L 284 mg/L	546 mg/L 168 mg/L 338 mg/L 383 mg/L	Yes No Yes Yes
[13]	DO	108.1 g CWW/L	130.2 g CWW/L	37.6 U/g CWW	39.7 U/g CWW	Yes
[14]	DO	124.0 g DCW/L	114.0 g DCW/L	22.0 g/L	19.0 g/L	Yes
[15]	$p^* k_{LA}$	80.3 g/L	59.7 g/L	13.1 g/L	6.25 g/L	Yes

Table 13 highlights all the problems encountered during the fermentation or scale-up process for each included study. For those that were resolved, the solution is also reported in Table 13. In some papers, the issues were mentioned but not resolved [9-10].

Table 13: Problems encountered, and solutions applied

Reference	Issue during/before scale-up	Resolution method
[8]	Initial carbon source (glucose, yeast extract) concentrations had a negative influence on product yield.	Optimization of carbon source concentrations was carried out prior to scale-up.
[9]	Plasmid stability	Not Resolved The difference between the two scales was not significant.
[10]	Hypoxia Lower growth and productivity	Not Resolved
[11]	Very low productivity (53% of the small-scale productivity) was obtained using calculated parameters for constant aeration number.	The aeration rate was recalculated using constant k_{LA} criteria.
[12]	None mentioned.	Not mentioned.
[13]	Growth inhibition	Inducer changed to galactose
[14]	A decrease in biomass yield	Substrate feeding strategy
[15]	Acetate overproduction Low yield in larger scale	Not Resolved

4. DISCUSSION

This review aimed to provide an overview of the process scale-up of recombinant protein production and to address the research questions that have become the key subheadings in this section, as shown below.

4.1. Summary of Evidence

To answer the first research question, the process scale-up methods or strategies that have been used with *E. coli* to produce recombinant proteins are summarized in Table 14. The constant k_{La} strategy was used in a total of five papers. Constant volumetric power consumption (P/V) was used in three included papers. Constant aeration as a scaleup strategy was employed in two papers as constant Q/V and three of the included papers as constant DO . Constant Reynolds number and constant tip speed strategies were each used in one paper. Constant geometry as a strategy was mentioned only in two of the included papers.

Table 14: Scale-up strategies employed in each study

Reference	Scale-up criteria						
	Constant DO	Constant k_{La}	Constant P/V	Constant Q/V	Constant Re	Geometrical similarity	Constant tip speed (nD_i)
[8]		✓		✓			
[9]		✓		✓		✓ (implied)	
[10]	✓						
[11]		✓	✓				
[12]		✓	✓		✓		✓
[13]	✓		✓				
[14]	✓					✓	
[15]		✓					
Frequency	3	5	3	2	1	2	1

From the definition of the process scale-up, *i.e.*, maintaining the production of the desired product at the large scale, it is possible to evaluate the success of the scale-ups conducted in each included study. This can be assessed by calculating the ratio of the biomass yields at the large scale to that of the small scale. Similarly, this ratio can be calculated for the recombinant protein product. A value greater than or equal to one indicates that the scale-up was successful. The calculation of scale-up efficiency, calculated using the ratio of recombinant protein yield in the larger scale to that of the small scale, as well as that of the biomass yields, is presented in Table 15.

Table 15: Evaluation of the success of scale-up

Reference	Constant Parameter	Scale Ratio ($V_{T,LS}/V_{T,SS}$)	Biomass Yield Efficiency ¹ of scale-up	Product Yield Efficiency ² of scale-up
[8]	k_{La} and Q/V	40	NA	1.0135
[9]	k_{La} and Q/V	10	NA	NA
[10]	DO	50	0.7	0.84
[11]	k_{La}	28	1.33	1.24
	P/V	28	0.67	0.61
[12]	k_{La}/k	28	1.5	1.92
	Re	28	0.54	0.59
	ND_i	28	1.04	1.19
	P/V	28	1.15	1.35
[13]	DO	60	1.20	1.06
[14]	DO	6.5	0.92	0.86
[15]	$p^* k_{La}$	2.3	0.74	0.48

¹Biomass yield efficiency here refers to the ratio of the biomass yield value for the large-scale fermentation to the biomass yield value for the small-scale fermentation. It is unitless. A value greater than or equal to one indicates a successful scale-up.

²Product yield efficiency here refers to the ratio of the product yield value for the large-scale fermentation to the biomass yield value for the small-scale fermentation. It is unitless. A value greater than or equal to one indicates a successful scale-up.

4.2. Scale-up Strategies Employed in the Included Studies

The seven parameters which were kept constant in the included studies were geometrical similarity, constant volumetric oxygen transfer coefficient (k_{LA}), constant volumetric power input (ratio of agitation power input per volume of liquid) (P/V), constant impeller tip speed (or maximum shear stress), constant Q/V (volumetric airflow rate per unit volume), constant impeller Reynolds number, and constant dissolved oxygen concentration. The selection of these parameters as scale-up criteria was mentioned in four studies [8, 12, 14-15] while the remaining four studies did not clearly justify the reason for the choice(s). The effects of inner vessel pressure and heat transfer were not mentioned in any of the included studies. Table 16 shows the selected scale-up criteria of some studies [4, 78-81] by highlighting their corresponding applications and limitations of each criterion.

Table 16: Scale-up criteria used and their features

No.	Scale-up criteria	Related equation	Applications	Limitations
1	Geometrical similarity	$D_{T2}/D_{T1} = (V_{T2}/V_{T1})^{1/3}$	<ul style="list-style-type: none"> Most fermentation processes for alcohol and organic acid production have followed the concepts of geometric similarity and constant power per unit volume. This is a prerequisite assumption for other scaleup approaches [4]. 	<ul style="list-style-type: none"> This assumes constant impeller geometry or diameter and the number of impellers. It is difficult to maintain geometrical similarity when it is used with other criteria in scale-up [4].
2	Volumetric oxygen transfer coefficient (k_{LA})	$(k_{LA})_1 = (k_{LA})_2$	<ul style="list-style-type: none"> The majority of aerobic systems have been scaled-up on the k_{LA} basis. 	<ul style="list-style-type: none"> k_{LA} values vary throughout the fermentation and are difficult to obtain a reliable value for it. Thus, the scale-up is complex and process-specific [79].
3	Constant impeller Reynolds number	$(NDi^2)_1 = (NDi^2)_2$ $Re = \rho NDi^2 / \nu$ $Re \propto NDi^2$	<ul style="list-style-type: none"> It is useful when the heat transfer rate from the fermentation broth to the cooling coils inside the bioreactor vessel is vital, as in the case of the use of thermophilic microorganisms. 	<ul style="list-style-type: none"> Since the effect of aeration is not considered, often this basis does not work well in scale-up [4].
4	Constant maximum shear	Impeller tip speed = πNDi	<ul style="list-style-type: none"> This scale-up criterion is used for possibly shear-sensitive fermentations where a maximum shear rate is calculated to prevent shear damage that can lyse the cells or influence cell growth and protein production. On the other hand, it is used in cases where the cells tend to form dense flocks, the minimum shear rate required to break-up these flocks must be known and applied. Useful for branched yeast and filamentous bacteria [4]. 	<ul style="list-style-type: none"> This is less useful for single-cell yeast and bacterial cultures. Often, P_g/V_L is lowered, and this affects aeration efficiency and thus must be coupled with keeping k_{LA} constant [4, 80].
5	Constant Gassed or Ungassed Power Per Unit Liquid Volume (P/V_L)	$(P/V_L)_1 = (P/V_L)_2$ $P/V \approx N^3/D^2$	<ul style="list-style-type: none"> It is efficient for turbulent flows in single-cell <i>E. coli</i> and yeast cultures [78]. Several aerobic fermenter systems have been scaled-up on the P/V basis including many 	<ul style="list-style-type: none"> Scale-up based on constant power per unit liquid volume can have an unnecessarily large motor size, making it impractical,

			antibiotic fermentations [81].	economically or technically, to apply [4].
6	Constant Q/V (constant VVM)	$N_A=Q/NDi^3$	<ul style="list-style-type: none"> It is useful when a simple approach that considers aerations is required, and sparger characteristics are not known [82]. 	<ul style="list-style-type: none"> The resulting superficial velocity values must be checked for reasonableness as foaming and flooding could occur at very high airflow rates [4].
7	Constant minimum dissolved oxygen (DO)	-	<ul style="list-style-type: none"> It is easy to achieve this by controlling operating conditions for facilities that have existing installed equipment [4]. 	<ul style="list-style-type: none"> The scale-up of methods to control the dissolved oxygen concentration, such as aeration and agitation rate, must be considered [4].

4.2.1. Constant Power per Unit Volume

Power consumption per unit volume can be used to represent the turbulence and degree of mixing in a bioreactor. As the culture scale increases, power requirements decrease as a result of an increase in pressure inside the vessel. By keeping the power per unit volume constant, many fermentations have been successfully scaled up. However, other consequences such as high costs and/or high shear effects must also be considered [82]. Generally, this criterion worked very well in the included studies. However, in one case the protein productivity decreased markedly when using this scale-up strategy [11]. Hence, power consumption per unit volume can be applied to recombinant protein production, along with another scale-up strategy for comparison of attainable protein yield.

4.2.2. Constant Oxygen Transfer

For aerobic fermentation, the dissolved oxygen concentration depends on the oxygen transfer rate (OTR) from the gas phase to the liquid, the oxygen transport rate from the liquid into the cell, and the oxygen uptake rate (OUR) by the microorganism for cellular functions such as cell growth, maintenance, and recombinant protein production. In turn, these factors are governed by the cell culture conditions within the bioreactor and the physical aspects of the bioreactors [4]. As the culture scale increases, it becomes more difficult to ensure available dissolved oxygen availability throughout the culture and oxygen often becomes the limiting nutrient for the fermentation process. Thus, parameters related to oxygen transfer become of high interest in scale-up to ensure that the oxygen is always above a critical level. This is often achieved using constant k_{LA} , but sometimes a minimum dissolved oxygen setpoint is controlled instead.

In the studies reviewed, sufficient oxygen transfer is the main problem in scale-up and takes priority. Three common methods can be used to correlate k_{LA} , namely:

1. Energy input criterion relating k_{LA} to the power input (P_g) and the superficial gas velocity (v_s), or Q/V , volumetric flow rate over volume,
2. The use of dimensionless numbers such as the Froude number (Fr), the gas flow number (FlG) and the ratio of the impeller and tank diameters (D_i/D_T), and
3. The gas hold-up in using the dispersion parameter, N/N_{cd} , where N_{cd} represents the minimum impeller speed required for all the medium to be in contact with the sparged gas.

The correlations that have been used to determine k_{La} in the included studies are presented in Table 17. The actual value of k_{La} was not provided in the included papers, except in [12].

Table 17: Correlations for k_{La}

Reference	Correlation for k_{La}	Value
[8]	$k_{La} = k(P_g/V_L)^\alpha (v_s)^\beta$ $k_{La} = 0.00048 N^{2.2} D_i^{2.4} Q^{0.52} (1/V)^{0.7} B^{0.8} J^{0.3}$	NA
[9]	$k_{La} = k(P_g/V_L)^\alpha (v_s)^\beta$ $k_{La} = 0.00048 N^{2.2} D_i^{2.4} Q^{0.52} (1/V)^{0.7} B^{0.8} J^{0.3}$	NA
[10]	NA	NA
[11]	$k_{La} = 2 \times 10^{-3} (P/V)^{0.7} (4Q/\pi D_T^2)^{0.2}$	NA
[12]	$k_{La} = k(P_g/V_L)^\alpha (v_s)^\beta$ $k_{La}/k = (4P_g/\pi D_T^2 H_L)^{0.4} (4Q/\pi D_T^2)^{0.2}$ $k_{La}/k = (4/\pi D^2)^{0.6} (N_p r D_i^5 N f_{fp} / H_L)^{0.4} n^{1.2} Q^{0.2}$	$8.7 \text{ W}^{0.4} \text{ m}^{-1} \text{ s}^{-0.2}$
[13]	NA	NA
[14]	NA	NA
[15]	$k_{La} = k(P_g/V_L)^\alpha (v_s)^\beta v^c$ $k_{La} = K Q^\alpha N_y D_i^{2.4} V_L^{y/3.15}$	NA

All the empirical correlations in Table 17 use a similar pattern that is the Van't Riet equation, relating power consumption and superficial gas velocity to k_{La} . These empirical correlations were probably chosen because of ease as compared to determining the values through various chemical or physical methods, providing comparable values to experimental values. As can be seen from the reviewed studies, it is best, in scale-up, to obtain k_{La} values themselves as scale-up criteria instead of factors the k_{La} value is affected by. However, obtaining accurate k_{La} values is still an issue, and the empirical models may not always give good estimates for k_{La} since it is influenced by many factors such as the geometry of the bioreactor, operating conditions, broth rheology, and the measurement method employed [4]. In the included studies that involved a comparison of several strategies, constant k_{La} remained the best option, giving the highest yield upon scale-up. This is in line with the literature available on the subject [83] and therefore it is best to determine k_{La} value, even when another strategy is applied.

4.2.3. Constant Aeration and/or Constant DO levels

Another way to scale-up by considering oxygen transfer focuses on constant aeration number, flow rate per unit volume or vessel volume, or constant oxygen saturation concentration. In the included studies, two papers considered constant Q/V as a scale-up criterion [8-9]. In both cases, the scale-up was reported as successful. Similarly, constant DO was used in three included studies [13, 14]. While this method seems simple, it had involved adjusting the agitation speed by trial and error, and manual adjustment, to control DO levels and ensure they are above a certain value. Even though a cascade can be programmed to control the bioreactor's DO above a certain level, the agitation requirement might be too high and this can cause shear-related problems if not set properly. Hence, this method is not very clear-set and the DO value may vary greatly throughout the fermentation.

4.2.4. Constant Reynold's Number

Scaling up using Reynold's number as a constant criterion resulted in a sharp decrease in impeller speed, volumetric power input, and k_{LA} values compared to the small-scale values. This effect can affect mixing adversely, as was observed in terms of the large-scale biomass yield and protein yield [12]. Usually, applying constant Reynold's number does not provide a successful scale-up [12]. Hence, only one included study had considered it here. The findings of the study agree with the available literature on the constant Reynolds number strategy [78, 83]. In conclusion, this strategy should not be a used for recombinant protein production using *E. coli* unless the protein product great affects flow properties in the bioreactor.

4.2.5. Constant Shear

As the volume of the bioreactor increases, it becomes more difficult to maintain homogeneity within the bioreactor, and thus mixing properties are also of interest. While it is of interest to have an impeller speed that will provide ample mixing, shear effects must also be considered as the cells may be disrupted, experience morphological changes, and growth and product formation slowed down, due to the high shear forces. Similarly, power consumption must also be considered when increasing speed. By considering the maximum allowable shear, the agitation speed can be controlled during scale-up to provide adequate mixing without damaging the cells. Constant shear as a criterion gave satisfactory yield values upon scale-up [12] and this scaleup strategy was therefore successful.

4.3. Challenges Encountered During Scale-Up

To answer the second research question of this review, regarding the effect(s) of various process and operation conditions on protein production in a scale-up, more papers must be available for synthesis. The number of papers and the omissions they contain, do not provide the researchers with enough data to confidently conclude the effects of the various process and operation conditions. Similarly, the included papers do not report the challenges faced during scale-up in detail and, in many cases, do not show a troubleshooting methodology. However, from the issues faced during scale-up, some considerations that could assist researchers can be learned. Besides considering a change of strain, at the lower scale, a change in carbon source might also be necessary. The first is to give more consideration to the working volume or bioreactor at both scales.

4.4. Risk of Bias Assessment in Individual Studies

The risk of bias assessment for individual studies is presented in Table 18. A study on the large-scale production of a recombinant protein [8] did not report on the yield obtained; however, it was qualitatively stated that the recombinant protein yields were comparable. Another study by Wong [9] was unclear and it was not possible to extract precise data from the graphics as published; however, graphically it was shown that the recombinant protein yields at both scales were comparable.

Table 18: Risk of bias in individual studies

Reference	Selection Bias	Detection Bias	Performance bias	Reporting Bias	Attrition bias	Statistical analysis	Funding	Evidence
[8]	Unclear	Unclear	Unclear	High	Unclear	Yes	NA	Biomass yield was measured, but actual values were not reported.
[9]	Unclear	Unclear	Unclear	High	Unclear	Yes	NA	Biomass yield was measured, but actual values were not reported.
[10]	Unclear	Unclear	Unclear	High	Unclear	NA	Funded	The choice of the scale-up strategy was not justified.
[11]	No	Unclear	Unclear	Unclear	Unclear	Yes	NA	Two scale-up strategies were compared.
[12]	No	Unclear	Unclear	Unclear	Unclear	Yes	NA	Four scale-up strategies were compared.
[13]	Unclear	Unclear	Unclear	Unclear	Unclear	Yes	Funded	The choice of the scale-up strategy was not justified.
[14]	Unclear	Unclear	Unclear	Unclear	Unclear	NA	Funded	The choice of the scale-up strategy was not justified.
[15]	Unclear	Unclear	High	Unclear	Unclear	Yes	Funded	The choice of the scale-up strategy was not justified.

4.5. Risk of Bias in the Review Process

The AMSTAR tool's checklist was used to assess the risk of bias in the writing of these articles. There is a risk of publication bias as well as selective reporting as statistically significant findings are more likely to be published. Thus, publication bias could have distorted the interpretation of the findings of this review. One reviewer reviewed all the publications and made the decision to exclude or include them, and this contributes to a risk of bias as well.

4.6. Limitations

Publication bias, as well as reporting bias, have significantly impacted this review. It is understood that many more scale-up studies have been conducted. However, they are usually carried out on behalf of certain companies and therefore they were not published in academic journals. Of the 72 full-text scale-up articles initially screened, numerous studies were relevant but were considered to be of low quality as they did not clearly state their scale-up criteria and parameters, report their scale-up methodology, including fermenter and impeller specifications, and/or challenges faced, even though they had scale-up as one of their keywords. Hence, they could not be included as quality articles. This issue has impacted the findings of this review as well. Publications on process scale-

up should report unbiased strategies, calculations, challenges, errors as well as complete findings, to help other researchers better understand scale-up. Publication bias, as well as reporting bias, have significantly impacted the number of publications included in this review, even though data from two decades were considered.

It is noted that the outcome for the scale-up is measured differently in different papers. For instance, some papers [14] reported dry cell weight (DCW) to OD_{600} , while others reported wet cell paste [13]. Some papers report protein activity instead of yield in grams per liter. This makes it difficult to compare different studies and synthesize results. It might be preferable in some cases to report productivity as a better assessment of production, as it includes fermentation time in the consideration.

5. CONCLUSION

The conclusions that may be drawn from this systematic review are that (1) choice of scale-up criterion or criteria significantly alters yields of recombinant protein from *E. coli*, and (2) The comparison of different fermentation systems revealed that the criterion of maintaining k_{LA} constant was found to be effective in all five included studies which employed it, and superior in terms of yield of protein and biomass in the two studies that compared it to other criteria. This can be explained by the importance of oxygen transfer in aerobic fermentation, as oxygen becomes the limiting substrate due to its low solubility [4]. Furthermore, with the effect of scale, heterogeneities such as dissolved oxygen concentration become more apparent and significant and k_{LA} accounts for them. This is in line with scale-up recommendations for aerobic fermentation in general. A constant impeller Reynolds number, on the other hand, resulted in an unsuccessful scaleup. This is consistent with previous findings in the literature, as the effect of aeration is not considered in this strategy. The evidence described in this review suggests such recommendations are warranted and it fortifies them.

There is a need to identify and include unpublished data, that may better fit the research questions posed. As such authors should strive to address this issue in scale-up research to allow for more reliable conclusions to be made. Scale-up from shake flasks to pilot-scale bioreactors were not included in this study, but they can be addressed in a separate study. This study can be extended to include other types of bioreactors, as well as single-use bioreactors.

ACKNOWLEDGEMENT

This study is funded by the Ministry of Higher Education, Malaysia via the Transdisciplinary Research Grant Scheme (TRGS/1/2018/UIAM/01/1/3). The authors report no conflict of interest. No ethical approval is required. No informed consent is required.

NOMENCLATURE

C^*	Liquid DO concentration at saturation
C_L	Measured liquid DO concentration
N	Impeller tip speed, m/s
D_i	Impeller diameter, m
D_T	Vessel diameter, m
DO	Dissolved oxygen
Fr	Froude number

H_L	Height of liquid, m
H_T	Height of vessel, m
k_{La}	Volumetric oxygen transfer coefficient, mmol/L.h
LS	Large-scale
N	impeller speed, rpm
N_A	Flow aeration number
N_{cd}	minimum impeller speed for all medium to be in contact with sparged gas
N_i	Number of impellers
N_P	Power number
OTR	Oxygen transfer rate, mmol/L.h
OUR	Oxygen uptake rate, mmol/L.h
P_g	Gassed power input
P_o	Ungassed power input
P_g/V	Gassed power input per unit volume
P_o/V	Ungassed power input per unit volume
Q	Volumetric air flow rate, L/min (lpm)
Q/V_L	Volumetric air flow rate per unit vessel liquid volume, L/min (vvm)
Re	Impeller-based Reynolds number
SS	Small-scale
T_{mix}	Mixing time, s
v_s	Superficial velocity, cm/s
V_L	Working volume of the vessel, L or m ³
V_T	Total volume of the vessel, L or m ³
X	Cell density, g/L
Y_{xO_2}	Cell yield on oxygen, g/mmol/L
ρ	Density, g/cm ³
ν	Liquid effective viscosity, g/cm.s
μ	Growth rate, /h

REFERENCES

- [1] Koopaei NN, Khadiv-Parsi P, Khoshayand MR, Mazlomi MA, Kebriaeezadeh A, Moloudian H, Solhi R, Aminian M (2018) Optimization of rPDT fusion protein expression by *Escherichia coli* in pilot scale fermentation: a statistical experimental design approach. *AMB Expr* 8 (1):135.
- [2] Rosano GL, Ceccarelli EA. (2014) Recombinant protein expression in *Escherichia coli*: advances and challenges. *Frontiers in Microbiology* 5.
- [3] Marisch K, Bayer K, Cserjan-Puschmann M, Luchner M, Striedner G. (2013) Evaluation of three industrial *Escherichia coli* strains in fed-batch cultivations during high-level SOD protein production. *Microb Cell Fact* 12 (1):58.
- [4] Garcia-Ochoa F, Gomez E. (2009) Bioreactor scale-up and oxygen transfer rate in microbial processes: An overview. *Biotechnology Advances* 27 (2):153-176.
- [5] Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6 (7):e1000097.
- [6] Pannucci CJ, Wilkins EG. (2010) Identifying and Avoiding Bias in Research. *Plastic and Reconstructive Surgery* 126 (2):619-625.
- [7] Higgins JPG, S. (Eds.) (2011) *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration.

- [8] Wong I, Hernández A, García MA, Segura R, Rodríguez I. (2002) Fermentation scale up for recombinant K99 antigen production cloned in *Escherichia coli* MC1061. *Process Biochemistry* 37 (11):1195-1199.
- [9] Wong I, García MA, Rodríguez I, Ramos LB, Olivera V. (2003) Fermentation scale up for production of antigen K88 expressed in *Escherichia coli*. *Process Biochemistry* 38 (9):1295-1299.
- [10] Schirmer EB, Golden K, Xu J, Milling J, Murillo A, Lowden P, Mulagapati S, Hou J, Kovalchin JT, Masci A, Collins K, Zarbis-Papastoitsis G. (2013) Reduction of product-related species during the fermentation and purification of a recombinant IL-1 receptor antagonist at the laboratory and pilot scale. *Biotechnol J* 8 (8):946-956.
- [11] Pérez RE, Lasa AM, Rodríguez RS, Menéndez EC, Suárez JG, Balaguer HD. (2006) Scale-up of recombinant Opc protein production in *Escherichia coli* for a meningococcal vaccine. *Journal of Biotechnology* 127 (1):109-114.
- [12] Pérez RE, Suárez JG, Diaz EN, Silva Rodríguez R, Caballero Menéndez E, Balaguer HD, Musacchio Lasa A. (2018) Scaling-up fermentation of *Escherichia coli* for production of recombinant P64k protein from *Neisseria meningitidis*. *Electronic Journal of Biotechnology* 33:29-35.
- [13] Restaino OF, Borzacchiello MG, Scognamiglio I, Porzio E, Manco G, Fedele L, Donatiello C, De Rosa M, Schiraldi C. (2017) Boosted large-scale production and purification of a thermostable archaeal phosphotriesterase-like lactonase for organophosphate decontamination. *J Ind Microbiol Biotechnol* 44 (3):363-375.
- [14] Babaeipour V, Mofid MR, Khanchezar S, Faraji F, Abolghasemi S. (2017) Bench-scale Overproduction and Purification of recombinant GCSF in *Escherichia coli* fed-batch process. *J App Pharm Sci* 7 (8):149-155.
- [15] Ma XX, Fan DD, Zhu CH, Shang ZF, Mi Y. (2014) New correlation of volumetric oxygen mass transfer coefficient for scale-up in aerobic fermentation of recombination *E. coli*. *Journal of Chemical and Pharmaceutical Research*, 6 (7):1810-1817
- [16] Bommarius B, Jenssen H, Elliott M, Kindrachuk J, Pasupuleti M, Gieren H, Jaeger KE, Hancock REW, Kalman D. (2010) Cost-effective expression and purification of antimicrobial and host defense peptides in *Escherichia coli*. *Peptides* 31 (11):1957-1965.
- [17] Chi-Wei Lan J, Chang C-K, Wu H-S. (2014) Efficient production of mutant phytase (phyA-7) derived from *Selenomonas ruminantium* using recombinant *Escherichia coli* in pilot scale. *Journal of Bioscience and Bioengineering* 118 (3):305-310.
- [18] Choi T-J, Geletu TT. (2018) High level expression and purification of recombinant flounder growth hormone in *E. coli*. *Journal of Genetic Engineering and Biotechnology* 16 (2):347-355.
- [19] Doig SD, O'Sullivan LM, Patel S, Ward JM, Woodley JM. (2001) Large scale production of cyclohexanone monooxygenase from *Escherichia coli* TOP10 pQR239. *Enzyme and Microbial Technology* 28:265-274
- [20] Esipov RS, Makarov DA, Stepanenko VN, Kostromina MA, Muravyova TI, Andreev YA, Dyachenko IA, Kozlov SA, Grishin EV. (2018) Pilot production of the recombinant peptide toxin of *Heteractis crispata* as a potential analgesic by intein-mediated technology. *Protein Expression and Purification* 145:71-76.
- [21] Chang F, Zhang X, Pan Y, Lu Y, Fang W, Fang Z, Xiao Y. (2017a) Light induced expression of β -glucosidase in *Escherichia coli* with autolysis of cell. *BMC Biotechnol* 17 (1):74.
- [22] Fang Z, Sha C, Peng Z, Zhang J, Du G. (2019) Protein engineering to enhance keratinolytic protease activity and excretion in *Escherichia coli* and its scale-up fermentation for high extracellular yield. *Enzyme and Microbial Technology* 121:37-44.
- [23] Fong BA, Wood DW. (2010) Expression and purification of ELP-intein-tagged target proteins in high cell density *E. coli* fermentation. *Microb Cell Fact* 9 (1):77.
- [24] Gąciarz A, Khatri NK, Velez-Suberbie ML, Saaranen MJ, Uchida Y, Keshavarz-Moore E, Ruddock LW. (2017) Efficient soluble expression of disulfide bonded proteins in the

- cytoplasm of *Escherichia coli* in fed-batch fermentations on chemically defined minimal media. *Microb Cell Fact* 16 (1):108.
- [25] Ge B, Tang Z, Zhao F, Ren Y, Yang Y, Qin S. (2005) Scale-up of fermentation and purification of recombinant allophycocyanin over-expressed in *Escherichia coli*. *Process Biochemistry* 40:3190–3195
- [26] Glazyrina J, Krause M, Junne S, Glauche F, Strom D, Neubauer P. (2012) Glucose-limited high cell density cultivations from small to pilot plant scale using an enzyme-controlled glucose delivery system. *New Biotechnology* 29 (2):235-242.
- [27] Goyal D, Sahni G, Sahoo DK. (2009) Enhanced production of recombinant streptokinase in *Escherichia coli* using fed-batch culture. *Bioresource Technology* 100 (19):4468-4474.
- [28] Hajihassan Z, Tilko PG, Sadat SM. (2018) Improved Production of Recombinant Human β -NGF in *Escherichia coli* – a Bioreactor Scale Study. *Polish Journal of Microbiology* 67 (3):355-363.
- [29] Hu W, Xiang J-Y, Kong P, Liu L, Xie Q, Xiang H. (2017) Expression and Characterization of a Single-Chain Variable Fragment against Human LOX-1 in *Escherichia coli* and *Brevibacillus choshinensis*. *Journal of Microbiology and Biotechnology* 27 (5):965-974.
- [30] Huang K-Y, Hu H-Y, Tang Y-L, Xia F-G, Luo X-Q, Liu J-Z. (2015) High-Level Expression, Purification and Large-Scale Production of l-Methionine γ -Lyase from *Idiomarina* as a Novel Anti-Leukemic Drug. *Marine Drugs* 13 (8):5492-5507.
- [31] Hui Q, Huang Z, Pang S, Yang X, Li J, Yu B, Tang L, Li X, Wang X. (2019) Two-hundred-liter scale fermentation, purification of recombinant human fibroblast growth factor-21, and its anti-diabetic effects on ob/ob mice. *Appl Microbiol Biotechnol* 103 (2):719-730.
- [32] Kangwa M, Yelemene V, Polat AN, Gorrepati KDD, Grasselli M, Fernández-Lahore M. (2015) High-level fed-batch fermentative expression of an engineered Staphylococcal protein A based ligand in *E. coli*: purification and characterization. *AMB Expr* 5 (1):70.
- [33] Kensy F, Engelbrecht C, Büchs J. (2009) Scale-up from microtiter plate to laboratory fermenter: evaluation by online monitoring techniques of growth and protein expression in *Escherichia coli* and *Hansenula polymorpha* fermentations. *Microb Cell Fact* 8 (1):68.
- [34] Kim E-K, Moon JC, Lee JM, Jeong MS, Oh C, Ahn S-M, Yoo YJ, Jang HH. (2012) Large-scale production of soluble recombinant amyloid- β peptide 1–42 using cold-inducible expression system. *Protein Expression and Purification* 86 (1):53-57.
- [35] Kim M-H, Gao W, Chung C-H, Lee J-W. (2017) Comparison of optimal conditions for mass production of carboxymethylcellulase by *Escherichia coli* JM109/A-68 with other recombinants in pilot-scale bioreactor. *Biotechnol Bioproc E* 22 (2):142-149.
- [36] Kim M-H, Kang D-U, Lee J-W. (2016) Construction of a recombinant *Escherichia coli* JM109/A-68 for production of carboxymethylcellulase and comparison of its production with its wild type, *Bacillus velezensis* A-68 in a pilot-scale bioreactor. *Biotechnol Bioproc E* 21 (5):601-611.
- [37] Kishore V, Nishita KP, Manonmani HK. (2015) Cloning, expression and characterization of l-asparaginase from *Pseudomonas fluorescens* for large scale production in *E. coli* BL21. *3 Biotech* 5 (6):975-981.
- [38] Krause M, Ukkonen K, Haataja T, Ruottinen M, Glumoff T, Neubauer A, Neubauer P, Vasala A. (2010) A novel fed-batch based cultivation method provides high cell-density and improves yield of soluble recombinant proteins in shaken cultures. *Microb Cell Fact* 9 (1):11.
- [39] Kumar R, Banoth L, Banerjee UC, Kaur J. (2017) Enantiomeric separation of pharmaceutically important drug intermediates using a Metagenomic lipase and optimization of its large scale production. *International Journal of Biological Macromolecules* 95:995-1003.
- [40] Lamppa JW, Tanyos SA, Griswold KE. (2013) Engineering *Escherichia coli* for soluble expression and single step purification of active human lysozyme. *Journal of Biotechnology* 164 (1):1-8.

- [41] Lee E-J, Lee B-H, Kim B-K, Lee J-W. (2013) Enhanced production of carboxymethylcellulase of a marine microorganism, *Bacillus subtilis* subsp. *subtilis* A-53 in a pilot-scaled bioreactor by a recombinant *Escherichia coli* JM109/A-53 from rice bran. *Mol Biol Rep* 40 (5):3609-3621.
- [42] Li J, Jaitzig J, Hillig F, Süßmuth R, Neubauer P. (2014) Enhanced production of the nonribosomal peptide antibiotic valinomycin in *Escherichia coli* through small-scale high cell density fed-batch cultivation. *Appl Microbiol Biotechnol* 98 (2):591-601.
- [43] Ma P, Varela F, Magoch M, Silva AR, Rosário AL, Brito J, Oliveira TF, Nogly P, Pessanha M, Stelter M, Kletzin A, Henderson PJF, Archer M. (2013) An Efficient Strategy for Small-Scale Screening and Production of Archaeal Membrane Transport Proteins in *Escherichia coli*. *PLoS ONE* 8 (10):e76913.
- [44] Marder LS, Lunardi J, Renard G, Rostirolla DC, Petersen GO, Nunes JES, de Souza APD, de O Dias A, Chies JM, Basso LA, Santos DS, Bizarro CV. (2014) Production of recombinant human annexin V by fed-batch cultivation. *BMC Biotechnol* 14 (1):33.
- [45] Morales-Álvarez ED, Rivera-Hoyos CM, Baena-Moncada AM, Landázuri P, Poutou-Piñales RA, Sáenz-Suárez H, Barrera LA, Echeverri-Peña OY. (2013) Low-Scale expression and purification of an active putative iduronate 2-sulfate sulfatase-Like enzyme from *Escherichia coli* K12. *J Microbiol* 51 (2):213-221.
- [46] Nozach H, Fruchart-Gaillard C, Fenaille F, Beau F, Ramos OHP, Douzi B, Saez NJ, Moutiez M, Servent D, Gondry M, Thaï R, Cuniasse P, Vincentelli R, Dive V. (2013) High throughput screening identifies disulfide isomerase DsbC as a very efficient partner for recombinant expression of small disulfide-rich proteins in *E. coli*. *Microb Cell Fact* 12 (1):37.
- [47] Ongey EL, Santolin L, Waldburger S, Adrian L, Riedel SL, Neubauer P. (2019) Bioprocess Development for Lantibiotic Ruminococcin-A Production in *Escherichia coli* and Kinetic Insights Into LanM Enzymes Catalysis. *Frontiers in Microbiology* 10:2133.
- [48] Park C-I, Lee J-H, Li J, Lee J-W. (2019) Enhanced Production of Carboxymethylcellulase by Recombinant *Escherichia coli* Strain from Rice Bran with Shifts in Optimal Conditions of Aeration Rate and Agitation Speed on a Pilot-Scale. *Applied Sciences* 9 (19):4083.
- [49] Pavankumar AR, Norén J, Singh L, Chandappa Gowda NK. (2014) Scaling-up the production of recombinant *Moringa oleifera* coagulant protein for large-scale water treatment applications. *RSC Adv* 4 (14):7136-7141.
- [50] Peng YY, Howell L, Stoichevska V, Werkmeister JA, Dumsday GJ, Ramshaw JAM. (2012) Towards scalable production of a collagen-like protein from *Streptococcus pyogenes* for biomedical applications. *Microb Cell Fact* 11 (1):146.
- [51] Pistorino M, Pfeifer BA. (2009) Efficient experimental design and micro-scale medium enhancement of 6-deoxyerythronolide B production through *Escherichia coli*. *Biotechnol Progress* 25 (5):1364-1371.
- [52] Rashev M, Surtees JA, Guarné A. (2017) Large-scale production of recombinant SawI in *Escherichia coli*. *Protein Expression and Purification* 133:75-80.
- [53] Restaino OF, Borzacchiello MG, Scognamiglio I, Fedele L, Alfano A, Porzio E, Manco G, De Rosa M, Schiraldi C. (2018) High yield production and purification of two recombinant thermostable phosphotriesterase-like lactonases from *Sulfolobus acidocaldarius* and *Sulfolobus solfataricus* useful as bioremediation tools and bioscavengers. *BMC Biotechnol* 18 (1):18.
- [54] Roy V, Roth R, Berge M, Chitta R, Vajrala S, Kuntumalla S, E. Schmelzer A, Schoner R. (2017) A bicistronic vector with destabilized mRNA secondary structure yields scalable higher titer expression of human neurturin in *E. coli*: A Bicistronic Vector With Destabilized mRNA. *Biotechnol Bioeng* 114 (8):1753-1761.
- [55] Ruiz J, Fernández-Castané A, de Mas C, González G, López-Santín J. (2013) From laboratory to pilot plant *E. coli* fed-batch cultures: optimizing the cellular environment for protein maximization. *J Ind Microbiol Biotechnol* 40 (3-4):335-343.
- [56] Chang S, Guo Y, Wu B, He B. (2017b) Extracellular expression of alkali tolerant xylanase from *Bacillus subtilis* Lucky9 in *E. coli* and application for xylooligosaccharides

- production from agro-industrial waste. *International Journal of Biological Macromolecules* 96:249-256.
- [57] Schmieder A, Cremer JH, Weuster-Botz D. (2016) Parallel steady state studies on a milliliter scale accelerate fed-batch bioprocess design for recombinant protein production with *Escherichia coli*. *Biotechnol Progress* 32 (6):1426-1435.
- [58] Shang L, Tian PY, Kim NJ, Chang HN, Hahn MS. (2009) Effects of Oxygen Supply Modes on the Production of Human Growth Hormone in Different Scale Bioreactors. *Chem Eng Technol* 32 (4):600-605.
- [59] Singh AK, Athmaram TN, Shrivastava S, Merwyn S, Agarwal GS, Gopalan N. (2013) Fermentation and downstream process for high yield production of *Plasmodium falciparum* recombinant HRP II protein and its application in diagnosis. *J Ind Microbiol Biotechnol* 40 (7):687-695.
- [60] Šiurkus J, Panula-Perälä J, Horn U, Kraft M, Rimšeliene R, Neubauer P. (2010) Novel approach of high cell density recombinant bioprocess development: Optimisation and scale-up from microlitre to pilot scales while maintaining the fed-batch cultivation mode of *E. coli* cultures. *Microb Cell Fact* 9:35.
- [61] Su E, Lu C, Ma X, Cai W, Zhu S. (2016) High-level production of *Arthrobacter aurescens* CYC705 nitrilase in *Escherichia coli* for biosynthesis of iminodiacetic acid: High-Level Production of Nitrilase. *Biotechnology and Applied Biochemistry* 63 (4):564-571.
- [62] Tan JS, Abbasiliasi S, Kadkhodaei S, Tam YJ, Tang T-K, Lee Y-Y, Ariff AB. (2018) Microtiter miniature shaken bioreactor system as a scale-down model for process development of production of therapeutic alpha-interferon2b by recombinant *Escherichia coli*. *BMC Microbiol* 18 (1):3.
- [63] Tripathi NK, Shrivastava A, Biswal KC, Rao PVL (2012) Development of a pilot-scale production process and characterization of a recombinant Japanese encephalitis virus envelope domain III protein expressed in *Escherichia coli*. *Appl Microbiol Biotechnol* 95 (5):1179-1189.
- [64] Valldor P, Miethling-Graff R, Dockhorn S, Martens R, Tebbe CC. (2012) Production of the 14C-labeled insecticidal protein Cry1Ab for soil metabolic studies using a recombinant *Escherichia coli* in small-scale batch fermentations. *Appl Microbiol Biotechnol* 96 (1):221-229.
- [65] Voulgaris I, Chatel A, Hoare M, Finka G, Uden M. (2016) Evaluation of options for harvest of a recombinant *E. Coli* fermentation producing a domain antibody using ultra scale-down techniques and pilot-scale verification. *Biotechnol Progress* 32 (2):382-392.
- [66] Wang W, Tang W, Yan M, He K, Yang L, Jiang L, Hua X, Yin L, Sun M, Li H. (2010) A bicistronic expression strategy for large scale expression and purification of full-length recombinant human parathyroid hormone for osteoporosis therapy. *Protein Expression and Purification* 69 (2):178-185.
- [67] Wang Z, Wang Y, Shi H, Su Z. (2012) Expression and production of recombinant cis-epoxysuccinate hydrolase in *Escherichia coli* under the control of temperature-dependent promoter. *Journal of Biotechnology* 162 (2-3):232-236.
- [68] Wu X, Tian H, Huang Y, Wu S, Liu X, Wang C, Wang X, Huang Z, Xiao J, Feng W, Li X. (2009) Large-scale production of biologically active human keratinocyte growth factor-2. *Appl Microbiol Biotechnol* 82 (3):439-444.
- [69] Xiao Y, Chen H-Y, Wang Y, Yin B, Lv C, Mo X, Yan H, Xuan Y, Huang Y, Pang W, Li X, Yuan YA, Tian K. (2016) Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in *Escherichia coli* and protection potency evaluation in cattle. *BMC Biotechnol* 16 (1):56.
- [70] Yang Y-N, Shan W-X, Wang P-W. (2017) Upscale production of a recombinant cyclodextrin glycosyltransferase from *Paenibacillus macerans* in *Escherichia coli*. *3 Biotech* 7 (3):207.
- [71] Ye X, Qi J, Yu D, Li S, Wu Q, Wu Y, Ren G, Han J, Li D. (2016) Pilot-scale production and characterization of PEGylated human FGF-21 analog. *Journal of Biotechnology* 228:8-17.

- [72] Zaslona H, Trusek-Holownia A, Radosinski L, Hennig J. (2015) Optimization and kinetic characterization of recombinant 1,3- β -glucanase production in *Escherichia coli* K-12 strain BL21/pETSD10 - a bioreactor scale study. *Lett Appl Microbiol* 61 (1):36-43.
- [73] Zhang M, Jiang X, Su Z, Lin J, Xiang Q, Yang Z, Huang Y, Li X. (2012) Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in *Escherichia coli*. *Appl Microbiol Biotechnol* 93 (2):613-621.
- [74] Zhang J, Suflita M, Fiaschetti CM, Li G, Li L, Zhang F, Dordick JS, Linhardt RJ. (2015) High cell density cultivation of a recombinant *Escherichia coli* strain expressing a 6- O - sulfotransferase for the production of bioengineered heparin. *J Appl Microbiol* 118 (1):92-98.
- [75] Zhao M, Wu F, Xu P. (2015) Development of a rapid high-efficiency scalable process for acetylated *Sus scrofa* cationic trypsin production from *Escherichia coli* inclusion bodies. *Protein Expression and Purification* 116:120-126.
- [76] Zhong G, Yu A, Shi B, Liu Y, Wu C. (2009) Pilot-scale production and purification of a staphylokinase-based fusion protein over-expressed in *Escherichia coli*. *Front Biol China* 4 (1):75-81.
- [77] Zhou M, Shi W, Yu F, Zhang Y, Yu B, Tang J, Yang Y, Huang Y, Xiang Q, Zhang Q, Yao Z, Su Z. (2019) Pilot-scale expression, purification, and bioactivity of recombinant human TGF- β 3 from *Escherichia coli*. *European Journal of Pharmaceutical Sciences* 127:225-232.
- [78] Junker BH. (2004) Scale-up methodologies for *Escherichia coli* and yeast fermentation processes. *Journal of Bioscience and Bioengineering* 97 (6):347-364.
- [79] Najafpour GD. (2007) *Bioprocess Scale-up*. In: *Biochemical Engineering and Biotechnology*. Elsevier, pp 287-331
- [80] Najafpour GD. (2015) *Biochemical engineering and biotechnology*. Second edition edn. Elsevier, Amsterdam Boston Heidelberg
- [81] Xu S, Hoshan L, Jiang R, Gupta B, Brodeur E, O'Neill K, Seamans TC, Bowers J, Chen H. (2017) A practical approach in bioreactor scale-up and process transfer using a combination of constant P/V and vvm as the criterion. *Biotechnol Progress* 33 (4):1146-1159.
- [82] Magdoui S, Saffar T, Guedri T, Tarek R, Brar SK, Blais JF. (2018) Practical Aspects and Case Studies of Industrial Scale Fermentation. In: *Microbial Sensing in Fermentation*. pp 267-298.
- [83] Marques MPC, Cabral JMS, Fernandes P. (2010) Bioprocess scale-up: quest for the parameters to be used as criterion to move from microreactors to lab-scale. *J Chem Technol Biotechnol* 85 (9):1184-1198.